&lt;p&gt;Cognitive Effects of Anticholinergic Load in Women with Overactive Bladder&lt;/p&gt;

Araklitis, George; Robinson, Dudley; Cardozo, Linda

doi:10.2147/cia.s252852

Cited by 37 publications

(42 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anticholinergic agents, [7] such as solifenacin and tolterodine, are used as the cornerstone of pharmacotherapy for OAB symptoms. However, they were accompanied by some bothering adverse effects, such as dry mouth, blurred vision, constipation, even cognitive effects, which were leading to poor adherence to the prescribed medications [8,9] . In 2011, mirabegron, a β3-adrenoceptor agonist, was developed as a potential alternative treatment for OAB symptoms and had a distinct mechanism of action from anticholinergic agents.…”

Section: Introductionmentioning

confidence: 99%

Monotherapy with mirabegron had a better tolerance than the anticholinergic agents on overactive bladder

Yi¹,

Yang²,

Yang³

2021

Medicine

View full text Add to dashboard Cite

Background: We conducted this meta-analysis to explore the tolerance of monotherapy with mirabegron (50 mg) on an overactive bladder, compared with a common dosage of anticholinergic agents.Materials and methods: A comprehensive search for all randomized controlled trials that evaluated the safety of mirabegron and anticholinergic agents on overactive bladder was performed, and we searched the Cochrane Central Register of Controlled trials databases, Pubmed, Embase, and relevant trials from 2013.02 to 2019.10.Results: Eight studies included 5500 patients with treatment of monotherapy on overactive bladder were identified. The total number of treatment-emergent adverse events had no significantly difference between two monotherapies (RR = 0.88 95%CI: 0.76-1.01; P = .08); however, patients would have a better tolerance with mirabegron (50 mg) in adverse events of dry mouth (RR = 0.42; 95%CI: 0.33-0.53; P < .01) and tachycardia (RR = 0.52; 95%CI: 0.29-0.94; P = .03); and there were no significant differences between two groups in hypertension (RR = 1.

show abstract

Section: Introductionmentioning

confidence: 99%

Monotherapy with mirabegron had a better tolerance than the anticholinergic agents on overactive bladder

Yi¹,

Yang²,

Yang³

2021

Medicine

View full text Add to dashboard Cite

show abstract

“…Recently, the use of antimuscarinic medications for OAB in women has received attention because of mounting evidence of an increased risk of cognitive impairment and dementia associated with high anticholinergic burden and long-term exposure. [21][22][23][24][25] The American Urogynecologic Society (AUGS) Consensus Statement 2017 Recommendations underscored the risks of cognitive impairment associated with antimuscarinic medications and suggested a reduction of anticholinergic burden by decreasing the dosage, as well as urged clinicians to consider intradetrusor onabotulinum A or nerve stimulation as alternative treatments. 26 The AUGS Clinical Consensus Statement 2020 Updated Recommendations reiterated the risks and further emphasized the use of alternative medications with low potential to enter and remain in the central nervous system.…”

Section: Current Clinical Recommendations and A Critical Dilemmamentioning

confidence: 99%

Evidence-Informed, Interdisciplinary, Multidimensional Action Plan to Advance Overactive Bladder Research and Treatment Initiatives: Directives From State-of-the-Science Conference on Overactive Bladder and Cognitive Impairment

Sanses

Zillioux

High

et al. 2022

UROGC

View full text Add to dashboard Cite

This article outlines an evidence-informed, interdisciplinary, multidimensional, comprehensive action plan for the American Urogynecologic Society to improve care of women with overactive bladder (OAB) while minimizing treatment-related adverse events, including cognitive impairment. It is a "call to action" to advance basic, translational, and clinical research and summarizes initiatives developed at the State-of-the-Science Conference on OAB and Cognitive Impairment to (1) develop framework for a new OAB treatment approach in women, (2) define research gaps and future research priorities, (3) champion health equity and diversity considerations in OAB treatment, (4) foster community and promote education to remove stigma surrounding OAB and urinary incontinence, and (5) elevate visibility and impact of OAB, by creating partnerships through education and engagement with health care professionals, industry, private and public payers, funding agencies, and policymakers.

show abstract

“…A variety of medications are available for treatment, but can have side‐effects that make some people reluctant to take them. Anticholinergics, especially, are difficult for the elderly to tolerate and may cause cognitive impairment 14 …”

Section: Impact Of Closuresmentioning

confidence: 99%

“…Anticholinergics, especially, are difficult for the elderly to tolerate and may cause cognitive impairment. 14 OAB is associated with anxiety and the one makes the other worse. Which comes first has been much debated without a definite conclusion.…”

Section: Impact Of Closuresmentioning

confidence: 99%

No longer at your convenience: the consequences of closing public lavatories

Woodhouse

2022

Trends Urol & Men's Health

View full text Add to dashboard Cite

show abstract

<p>Cognitive Effects of Anticholinergic Load in Women with Overactive Bladder</p>

Cited by 37 publications

References 63 publications

Monotherapy with mirabegron had a better tolerance than the anticholinergic agents on overactive bladder

Monotherapy with mirabegron had a better tolerance than the anticholinergic agents on overactive bladder

Evidence-Informed, Interdisciplinary, Multidimensional Action Plan to Advance Overactive Bladder Research and Treatment Initiatives: Directives From State-of-the-Science Conference on Overactive Bladder and Cognitive Impairment

No longer at your convenience: the consequences of closing public lavatories

Contact Info

Product

Resources

About